All In Biotech

Drug Trial Radar · NCT04281992

Treatment of Diabetic Foot Ulcers With AUP1602-C

A Phase 1/2A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Single and Repeated Doses of AUP1602-C as Topical Treatment of Diabetic Foot Ulcers

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Jan 28, 2020

Primary completion

Mar 20, 2023

Study completion Mar 20, 2023

Sponsor

Lead sponsor
Aurealis OyIndustry
Sponsor type
Industry
First posted
Feb 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part phase 1/2A study performed in diabetic foot ulcer (DFU) patients with chronic non-healing wounds to investigate the safety and efficacy of AUP1602-C.

Conditions

  • Diabetic Foot Ulcer

Interventions

  • AUP1602-CBiological

    AUP1602-C is topically applied on chronic wounds and covered by wound dressing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and potential dose-limiting toxicities (DLTs)Time frame: 4 weeks
  2. Incidence of Treatment-Emergent Adverse EventsTime frame: 6 months
  3. Incidence of Wound ClosureTime frame: 6 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Medizinische Hochschule Hannover (MHH) CRC Core Facility

    Hanover, Germany

  • Mikomed

    Lodz, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.